Astellas sells US production site to APP
This article was originally published in Scrip
Astellashas sold a US manufacturing facility in Grand Island, New York, toAPP Pharmaceuticals. The move forms part of a wider reduction in production facilities under Astellas's current mid-term business plan, which calls for cutting the number of these to around 10 worldwide by April 2011. The Japanese firm will continue to lease the facility from APP until next spring, when it will transfer the production of the atopic dermatitis product Protopic (topical tacrolimus) from there to its Toyama plant in Japan. APP, a US firm specialising in generic injectables, already has operations on Grand Island and will offer employment to most of the 90 or so employees at the former Astellas facility.